Prihlásiť sa Zaregistrujte sa zadarmo

SMA 50 spoločnosti Beam Therapeutics

Aká je hodnota metriky SMA 50 spoločnosti Beam Therapeutics?

Hodnota metriky SMA 50 spoločnosti Beam Therapeutics Inc. je $27 -12.05%

Aká je definícia metriky SMA 50?



SMA 50 (Simple Moving Average 50) je priemerná cena akcie za posledných 50 dní vypočítaná ako nevážený priemer z predchádzajúcich 50 záverečných cien.

Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.

Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.

SMA 50 spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Beam Therapeutics

Čomu sa venuje spoločnosť Beam Therapeutics?

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Firmy s metrikou sma 50 podobnou spoločnosti Beam Therapeutics